Blackstone Inc’s Cardlytics CDLX Stock Holding History

Blackstone Inc’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,000	Closed	-$2.03M	–	181
2024 Q1	$2.03M	Buy	+14,000	New	+$1.18M	0.01%	117

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

PIP

PB Investment Partners Burlingame, California $127M AUM 0.83% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

WPM

Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return

BCM

Brightlight Capital Management Westport, Connecticut $101M AUM 23.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Blackstone Inc's CDLX Position: Q2 2024 in Review

Blackstone Inc sold out of Cardlytics (CDLX) in Q2 2024, closing a stake of 14,000 shares — an estimated $2.03M sold.

Blackstone Inc first reported a position in CDLX in Q1 2024 and held it in 1 quarter. The position peaked at $2.03M in Q1 2024. 127 funds tracked by Wall St. Rank hold CDLX as of Q2 2024.

Blackstone Inc reported no remaining Cardlytics position as of Q2 2024 after selling out during the quarter.
Blackstone Inc sold 14,000 Cardlytics shares in Q2 2024, an estimated $2.03M.
Blackstone Inc first reported a position in Cardlytics in Q1 2024 and held it in 1 quarter.
Blackstone Inc's Cardlytics position peaked at $2.03M in Q1 2024.
127 funds tracked by Wall St. Rank held Cardlytics as of Q2 2024.

Based on Blackstone Inc's 13F filing for Q2 2024, filed 14 Aug 2024.